Abstract
A Preliminary Cost-Effectiveness Analysis of Low Dose Rivaroxaban Versus Placebo for the Prevention of Stroke and Cognitive Impairment in Non-Valvular Atrial Fibrillation Patients at Low Risk of Stroke
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
